ASA Annual Report 2025 Is Here
Link to the report We’re proud to share the Angelman Syndrome Alliance’s Annual Report 2025 — “Together for Science and Hope.” This year reflected the strength of our global community. From a record wave of research proposals for the 2026 ASA Grant, to our members’ meeting in Hamburg, to a gathering of leading researchers in […]
Angelman Syndrome Alliance Announces the 2026 Scientific Research Grant Winners
The Angelman Syndrome Alliance (ASA) is proud to announce the recipients of its 2026 Scientific Research Grants. This year’s call for proposals attracted exceptionally high-quality research projects, reflecting the growing momentum, innovation, and dedication within the Angelman syndrome research community. The final funding decision was made through a vote by ASA’s 12 member organisations, ensuring […]
ASA members Meeting Hamburg 2025
The ASA Members Meeting in Hamburg brought together representatives from across Europe and beyond to reflect on progress and plan ahead. Members confirmed over €270,000 in commitments for the 2026 research grant and reaffirmed ASA’s central focus on supporting basic and translational research. Updates were shared on ongoing projects and upcoming conferences, including the Kyoto […]
ASA-Funded Research Published in Human Cell
We are excited to announce the publication of the second scientific paper from our ASA-funded research project, now available in Human Cell. In this study, led by Simão Rocha and colleagues, the team successfully generated three independent induced pluripotent stem cell (iPSC) lines derived from individuals with paternal uniparental disomy of chromosome 15 (patUPD15)—a rare […]
Community Update Phase 3 Trials – Ultragenyx & Ionis
ANGELMAN SYNDROME PHASE 3 TRIALS — COMMUNITY UPDATE (Webinar recorded: 4 Sep 2025) Video here: https://youtu.be/TenTbLp9pIk WHO HOSTED• FAST• ASA ULTRAGENYX — GTX-102 (antisense oligonucleotide targeting UBE3A-ATS)• Phase 1/2 (open-label; ages 4–17, maternal deletion; data cut Sep 2024)– Signals of improvement vs natural history in cognition (Bayley-4), receptive communication, sleep, gross motor, and behavior (ABC-C).– […]
Year End report 2024 published
The ASA year report for 2024 has been published: http://angelmanalliance.org/wp-content/uploads/2025/08/ASA-Year-End-report-2024.pdf
9th Scientific Conference – September 2026 Japan
Scientific call for proposals: ASA Grant 2026
The Angelman Syndrome Alliance (ASA) would like to announce our sixth grant call, to fund research for Angelman syndrome, open to teams both in Europe and outside of Europe. Key dates Background The Angelman Syndrome Alliance (ASA) is a non-profit organisation registered in the Netherlands, created by a partnership of organizations from around the world […]
Angelman Think tank
Sponsored by ASA & ASF 15 leading researchers from around the world gathered for one dynamic symposium in Lisbon, February 2025. Focused discussions on research priorities and therapeutic goals. The summit marked a pivotal step in forging a global future for research grants — strengthening collaboration, aligning priorities, and building momentum toward meaningful therapeutic breakthroughs […]
ASA becomes an official member of EURORDIS-Rare Diseases Europe
Exciting news! In October 2024, ASA became an official member of EURORDIS-Rare Diseases Europe, the European federation of rare disease patient organisations. EURORDIS has been the voice of rare disease patients, empowering, advocating for and engaging patients for over 25 years, helping to raise the patient perspective in Europe. This membership can help YOU as […]